Ocumetics Reports Improvement in Six Month First-in-Human Results Meaningful Improvements in Patient Quality of Life
(TheNewswire)
Key Highlights
Vision performance: Clinicaloutcomes exceed expectations, with all patients experiencingcontinuing vision improvements
Safety profile: Continues tomeet expectations
Quality-of-life improvements:Anecdotally, all patients reported life changing results fromlens implantations
Technology validation: Resultsreinforce the expected performance of Ocumetics’ inauguralaccommodating intraocular lens
Momentum: Forward momentumcontinues, with lens design enhancements in manufacturing and testingphase
Webinar: April 22, 2026, 4:00 PMET. Register at www.ocumetics.com/webinar
Calgary, Canada – TheNewswire - April 20, 2026 -Ocumetics TechnologyCorp. (TSV:V OTC |OTCQB: OTCFF |FRA: 2QBO)(“Ocumetics” or the “Company”),a leader in next generation vision technology,is pleased to announce highly encouragingsix-month postoperative results from the firstgroup of patients in its first-in-human (FIH) clinical study of theOcumetics Accommodating Intraocular Lens (“OcumeticsLens”).
Six months after surgery, patients who received theOcumetics Lens have achieved clinical outcomes that meet and exceedthe Company’s expectations. Group One patients entered the studywith very poor vision, including one individual considered to belegally blind. At six months post-surgery, patients continue todemonstrate improved vision and stable visual acuity, alongside astrong safety profile. Patients have also experienced real worldtransformation in their daily lives.
“After six months, what stands out most is not justthe clinical performance of the Ocumetics Lens, but the profoundimpact on patients’ quality of life,” said Dean Burns, Presidentand CEO of Ocumetics. “Patients who entered this study with severelyimpaired vision are now reading, driving, and living independentlyagain. We’re developing a technology that dramatically improvespeople’s quality of life and we couldn’t be happier.”
Ocumetics continues to leverage surgeon feedback andpatient experience into ongoing product enhancements. Updated lensrefinements are currently in manufacturing and testing, supporting theplanned initiation of Group Two surgeries.
“The measurable improvements in visual acuity andconsistency we are seeing at six months give us tremendous confidenceas we advance to the next phase of our clinical program,” addedBurns. “We are not only validating our technology, we aredemonstrating its real-world impact. Our focus now is to build on thissuccess, further optimize performance, and bring this life changingsolution to more patients.”
Ocumetics looks forward to initiating Group Twosurgeries following completion of lens testing, as the Companycontinues to advance its mission of transforming vision correctionthrough innovation.
Ocumetics Webinar
Join Ocumetics Director and CEO, Dean Burns, for anexclusive webinar covering our six-month study results and importantupdates on our FIH study.
Date: Wednesday, April 22, 2026
Time: 4:00 PM ET
Register at www.ocumetics.com/webinar
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that isdedicated to developing advanced vision correction solutions thatenhance the quality of life for patients. Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.
Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed a dynamic intraocular lens that fits withinthe natural lens compartment of the eye, potentially to eliminate theneed for corrective lenses. It is designed to allow the eye’snatural muscle activity to shift focus from distance to near,providing clear vision at all distances without the help of glasses orcontact lenses, and without perceptible time lag.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Company mentionedabove. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, whileconsidered reasonable, are subject to known and unknown risks,uncertainties, and other factors which may cause the actual resultsand future events to differ materially from those expressed or impliedby such forward-looking statements. Such factors include but are notlimited to: operational matters, historical trends, current conditionsand expected future developments, access to financing as well as otherconsiderations that are believed to be appropriate in thecircumstances. There can be no assurance that such statements willprove to be accurate, as actual results and future events could differmaterially from those anticipated in such statements. Accordingly,readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required bylaw.
Copyright (c) 2026 TheNewswire - All rights reserved.
NASDAQ: OTC:CC
OTC:CC Trading
-5.26% G/L:
$0.27 Last:
139,289 Volume:
$0.295 Open:
